I am a medical oncologist specializing in the treatment of prostate cancer. I’m fortunate to be a member of both the Immunotherapeutics Service and the Genitourinary Service because advances in one field can often help in another.
On the Immunotherapy Service, I evaluate novel immunotherapies for phase I clinical trials and treat patients throughout MSK with different types of metastatic cancer who are participating in these studies. My research also focuses on immunologic strategies for the treatment of metastatic disease. I’ve seen some of the wonderful successes that immunotherapy has achieved in cancers such as Hodgkin’s lymphoma and lung cancer, and I strive to find the right immunotherapy for prostate cancer patients who may benefit from this approach.
For this reason, we offer men with metastatic prostate cancer and those at high risk for disease recurrence access to trials. Our clinical trials for prostate cancer include those that test new agents, imaging techniques, and therapies that target pathways we believe are important in prostate cancer. Some patients perceive clinical trials as a last resort, but this is often not the case. I want to be certain that my patients know all their options, whether it is standard-of-care treatments or a cutting-edge clinical trial.
On the Genitourinary Service, I’m part of a dedicated team that includes radiation oncologists and surgeons. My colleagues and I take an individual approach to each person’s care. In my clinical practice, I treat men with recurrent and metastatic prostate cancer as well as provide consultation to men with localized disease who are trying to decide upon the most appropriate treatment option for them — for example, choosing between surgery, active surveillance, and radiation therapy.
I chose to work in oncology because I wanted to care for people at a critical time in their lives. I love working at MSK because I believe we’re all here for the right reasons: We feel privileged to care for patients; we’re committed to science, research, and innovation; and we’re proud to offer patients access to the latest and most effective treatments available.
- Clinical Expertise: Prostate Cancer; New Investigational Agents, including Immunotherapy
- Awards and Honors: Phi Beta Kappa; Recipient, Clinical Investigator Track (funded master’s in clinical research during medical residency); American Society of Hematology Trainee Award; American Society of Clinical Oncology (ASCO) Merit Award
- Languages Spoken: English
- Education: MD, Stony Brook University Medical School; MSc, University of Virginia Department of Public Health Sciences
- Residencies: University of Virginia Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Karen A. Autio
- A Phase I Study of a Vaccine-Based Immunotherapy (PrCa VBIR) for Prostate Cancer
- A Phase I Study of AM0010 in Patients with Advanced Solid Tumors
- A Phase I Study of the Immune Activity and Safety of IMC-CS4 in Patients with Advanced Breast or Prostate Cancers
- A Phase II Study of Degarelix plus Ipilimumab Immunotherapy with Radical Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer
Clinical Trials Co-Investigated by Karen A. Autio
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more